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In vivo calibration of a subcutaneous glucose sensor
for determination of subcutaneous glucose kinetics
G. Velho*, Ph. Froguel*, D.R. Thévenot** and G. Reach*
ABSTRACT. The aim of this work was to develop a method for calibrating in vivo a subcutane¬
ous glucose sensor; this calibration procedure was used to investigate the kinetics of the
estimated subcutaneous glucose concentration during variations in blood glucose level. These
experiments were performed in anaesthetized rats: 1) In 25 animals, glycaemia was decreased
from 5.8 ± 0.2 to a 2.9 ± 0.2 mmol/1 plateau, following the intravenous injection of 1 unit of
insulin. This drop was followed by a decrease in the signal amplitude with a 5 m in time lag, from
13.54 ± 1.09 to 10.28 ± 1.05 nA (p < 0.01); 2) These two steady states allowed to perform a
two-point in vivo calibration of the sensor and to calculate the apparent subcutaneous glucose
level during subsequent glucose administration: a) Following a continuous glucose infusion
(n = 6) that increased glycaemia within 35 min to a 5.6 ± 0.4 mmol/1 plateau, the subcutaneous
glucose level increased to a 5.1 ± 0.2 mmol/1 plateau (NS); when glycaemia was increased to 11.3
i 0.3 mmol/1 (n = 7), subcutaneous glucose concentration raised to 10.7 ± 0.4 mmol/1 (NS); b) In
contrast, after a glucose bolus (n ^ 7), the glycaemic peak at 2 min was 12.4 ± 0.9 mmol/1, while
the subcutaneous glucose peak, observed at 2 min, was only 6.2 ± 0.6 mmol/1 (p < 0.01). We
conclude, therefore, that under steady state conditions, the apparent subcutaneous glucose
concentration reflects blood glucose level, thus validating the subcutaneous tissue as a site for
the implantation of a glucose sensor to be used in a closed-loop insulin delivery system.
INTRODUCTION
Glucose sensors are an essential part of closed-loop
insulin delivery systems in which an electric signal
is generated by the sensor, as a function of glucose
concentration, and is processed by a computer to
regulate the flow rate of a pump delivering insulin
(1). Most of the sensors proposed so far consist of a
glucose electrode in which the oxidation of glucose
by glucose-oxidase is responsible for the genera¬
tion of the signal (2). In the past few years, needle
type glucose sensors have been proposed for sub¬
cutaneous implantation (3-5). Indeed, a subcu¬
taneous implantable sensor would be ol great in¬
terest, since it could allow for easy replacement in
case of impairment of the sensor performances.
However, if a subcutaneous sensor is supposed to
work as part of a closed-loop insulin deliverv svs-
tem, intended to regulate blood glucose (BG) level
in diabetic patients, this assumes that the relation¬
ship between the generated current and RG con¬
centration is well defined. As things now stand, the
relationship between the true subcutaneous glu¬
cose concentration, which will be monitored, and
the BG level is unknown, since the former is not
measurable.
The aim of this work was, therefore, to character¬
ize these relationships. As a first step, we defined a
method for calibrating in vivo a subcutaneous glu¬
cose sensor, namely for determining, for a given
sensor, the variation in the current corresponding
. to a change in BG concentration. This in vivo
sensitivity coefficient was then used to determine
r
from the sensor output an apparent subcutaneous
glucose concentration and to estimate its varia¬
tions occurring during modifications of BG, con¬
centrât ions. These experiments were performed in
anaesthetized rats.
METHODS
Needle type glucose sensor
The design oi 'the sensor was modified from Shi-
chiri et al. (3). Briefly, the cathode was made of a
steel needle (23G), coated with gold or silver by
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electrolysis (Usiflamme, Saint Gratien, France).
The anode was formed by the tip of a platinum
wire, melted by a gas flame to form a microsphere
( 1 mm diameter), then electrically isolated inside a
polyethylene catheter (Biotrol, Paris, France) and
cast in an epoxide resin inside the cathode needle.
The electrode tip was then dipped into a suspen¬
sion of 2000 IU/ml glucose oxidase (Grad II,
Boehringer Mannheim, Mannheim, W. Germany)
and 1000 IU/ml heparin (H-108, Choay, Paris,
France) in acetone and ethanol (1:1 volume) con¬
taining 25% cellulose acetate (Prolabo, Paris,
France). Alter air drying, it was dipped into a 1%
glutaraldehyde hydric solution (Prolabo), and
again allowed to air dry. It was then dipped in a
solution of 5% polyurethane (EG85A, Thirmedies,
Woburn Mass., ILS.A.) in dimethylformamide
and tetrahydrofuran (1:9 volume, Prolabo). Forty
to 50% of the prepared sensors had satisfactory in
vitro linearity range (higher than 15 mmol/1) and
response time (t,)()(i shorter than 1 min). Other
sensors were discarded. Sensors were stored dry at
4° C, between preparation and implantation (3 to
10 days). Each experiment (n =25) was performed
with a different sensor, to make sure that the
calibration results were independent of the charac¬
teristics of a given sensor.
In vitro calibration of the sensor
The sensor was connected to an amperometric unit
(PRG-Del, Tacussel Electronique, Villeurbanne,
France) imposing a 650 mV voltage difference be¬
tween the anode and the cathode and allowing for
current recording (pen recorder SE 120, Goerz
Electro, Vienna, Austria), expressed in nanoam-
peres. Before each in vivo experiment, the charac¬
teristics of the sensor (i.e. the in vitro sensitivity,
expressed in nA/mmol/1 glucose, the linearity
range and the response time) were determined in
physiological saline solution by recording the basal
sensor current (I,,) for 30-60 min (until signal
stabilization), and the sensor response to stepwise
increases in the glucose concentration. This in
vitro study was repeated alter explantation of the
sensor.
In vivo calibration: determination of the in vivo sensi¬
tivity coefficient
Each experiment was carried out with a different
animal (n — 25). Overnight fasted male Wistar rats
(250-300 g body weight, Janvier, Saint Berthevi,
France) were anaesthetized with pentobarbital (50
mg/kg intraperitoneally, ( .lin Midy, Saint Jean de
la Ruelle, France), and polyethylene (Biotrol 3,
Biotrol, France) and silicone (Silastic 602-135,
Dow Corning, Midland Mich, U.S.A.) catheters
were inserted respectively into the left jugular vein
and homolateral carotide artery, for glucose or
insulin injection, and for blood sampling for the
determination of BG concentration. After the in
vitro characterization, the sensor was implanted in
the subscapular subcutaneous tissue by blunt dis¬
section. Animals were kept spontaneously brea¬
thing under a flow ol carbogen (02:C0.>, 95:5) and
warmed under a lamp.
At least 1 hr after surgery, when BG and the sensor
output were stable, 1 U of insulin (Endopancrine
U40, Organon, Saint Denis, France) was injected
through the jugular catheter. Blood samples (0.3
ml) were serially drawn through the carotid cathe¬
ter, from —10 to 50 min, with a 5 min interval.
Samples were immediately centrifuged and plasma
glucose concentration was determined with a glu¬
cose analyzer (Beckman, Fullerton Ca., U.S.A.).
Following insulin injection, the sensor output de¬
creased to reach a plateau, as did the BG concen¬
tration. The pre-insulin and post-insulin steady
states of the BG level and of the sensor output
made it possible to calculate, by a two-point cali¬
bration of the sensor, an in vivo sensitivity coeffi¬
cient, expressed in nA/mmol/1, as the ratio be¬
tween the decrease in the sensor current and the
decrease in glucose concentration, and an extrapo¬
lated in vivo residual current (I0) which would be
observed in the absence of glucose.
In the experiments where glucose was continuous¬
ly administered after the insulin-induced hypogly-
caemia (see below), a second plateau was reached
both lor the BG concentration and the sensor sig¬
nal. It was therefore possible to calibrate the sen¬
sor a second time and to calculate, under these new
conditions, a second in vivo sensitivity coefficient
based on these pre and post-glucose infusion pla¬
teaus.
Determination of subcutaneous glucose concentration
The in vivo sensitivity coefficient, determined inJ ' »
each individual experiment was used to calculate
the apparent subcutaneous glucose level. This es¬
timation of subcutaneous glucose was obtained by
subsl racting from the sensor current, observed at a
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given time, the in vivo residual current (In), and
then by dividing tlie resultant current by the sensi¬
tivity coefficient. This calculation was carried out
in three situations: the insulin-induced hypogly-
caemia itself and the subsequent i.v. glucose ad¬
ministrations, either as a continuous glucose infu¬
sion (20 to 60 mg/kg/min) using an infusion pump
(Infu 362, Datex, Uhwiesen, Switzerland), or as a
glucose bolus (0.5 g/kg), These glucose adminis¬
trations were performed shortly after a stable hy-
poglycaemic level was achieved.
Expression of results .and statistics
All data in text and figures are given as mean it
SEM, and their statistical significance was assessed
by the two-tail paired t-test.
RESULTS
In vitro characteristics of the sensors
When assessed in vitro, respectively before implan¬
tation and after explantation, the linearity range of
the sensor response was up to 18.0 it 0.9 and 15.3
± 0.9 mmol/1 of glucose (n = 25), and its response
lime (tm) to each glucose increment was 44 ± 4
and 42 it 2 seconds. The in vitro sensitivity of the
sensor, was 0.82 dt 0.10 and 0.92 it 0.1 nA/
mmol/1 and the current observed in the absence of
glucose (I,,) 8.04 ± 1.05 and 7.73 ± 1.18 nA,
before and after the in vivo experiment, respective-
•y-
In vivo calibration
Following the i.v. injection of 1 U of insulin (Fig. 1),
BG level decreased from 5.8 ± 0.2 to a 2.9 it 0.2
mmol/1 plateau and the current generated by the
sensor decreased, with a five min time lag, from
13.54 ± 1.09 to 10.28 it 1.05 nA (n = 25,p <0.01).
The high amplitudes of the SEM reflect the variabil¬
ity of the 25 different sensors' sensitivity coeffi¬
cient. The in vivo sensitivity coefficient calculated,
in each experiment, by this procedure was 1.15 ±
0.10 nA/mmol/1 glucose (p < 0.05 versus the in
vitro value). The extrapolated signal output for 0
mmol/1 glucose concentration (I,,) was 7.00 it 1.13
nA (N.S. versus the in vitro values). The correlation
coefficient for the signal amplitude (nA) vs BG level
(mmol/1) was in each experiment greater than 0.96.
Estimation oj the subcutaneous glucose concentration
Figure 2 represents the change in subcutaneous
glucose concentration, during insulin-induced hy-
poglycaemia, calculated from the sensor output
(Fig. 1) and taking into account in each experi¬
ment the respective in vivo sensitivity coefficient.
The curve reflects the changes in BG levels with
5-min delay. One must note that after the trans¬
formation o( the data, the variance of the estimat¬
ed subcutaneous glucose concentration was, at any
time, similar to that of BG. In 6 of these experi¬
ments, a 20 mg/kg/min glucose infusion was in¬
itiated shortly after the insulin-induced hypogly-
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Fig. 1 - Plasma glucose concentration (closed circles) and
sensor output (solid line) following the injection of 1 U of
insulin at time zero (mean ± SEM, n = 25).
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Fig. 2 - Plasma glucose concentration (closed circles), and
apparent subcutaneous glucose level (closed squares) calcu¬
lated from Figure 1, following insulin injection (mean ±
SEM, n = 25).
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caemic plateau was reached (Fig. 3). It increased
the RG concentration from 3.5 ± 0.5 mmol/1 to a
5.6 ± 0.4 mmol/I plateau. In the meantime, the
estimated subcutaneous glucose level rose to a 5.1
± 0.2 mmol/1 plateau (NS). In 7 other experi¬
ments (Fig. 3), glucose infusion rate was progres¬
sively increased from 20 to 60 mg/kg.min-1 to
reach a higher BG concentration. Blood glucose
increased progressively from 2.5 ± 0.2 to 11.3 ±
0.3 mmol/1 and the estimated subcutaneous glu¬
cose concentration increased, with a 5 min time
lag, to reach 10.7 ± 0.4 mmol/1 at 40 min (NS).
Figure 4 represents the correlation between the
estimated* subcutaneous glucose concentrations
and BG levels reached at the different plateaus
obtained during these series of experiments (21
values obtained with 7 different sensors, which are
represented by different symbols). As can be seen,
for each sensor, these two parameters were linear¬
ly correlated, the mean value of the V1 coefficient
being 0.9987 ± 0.0002 (n = 7). This figure was
obtained by using only stationary levels of BG and
sensor current observed before and after insulin or
glucose infusions, with at least 5 min of stable
levels, thus overcoming the bias which would be
introduced by the time lag between changes in
blood and subcutaneous glucose concentrations.
After a 0.5 mg/kg glucose bolus injection (n = 7,
Fig. 5), the peak in BG concentration, at 2 min, was
12.4 it 0.9 mmol/1, while the apparent subcutane¬
ous glucose peak, also observed at 2 min, was only
6.2 ± 0.6 mmol/1 (p <0.01 ). Both the BG concen¬
tration and the estimated subcutaneous glucose
level returned to basal at 30 min (3.1 ±0.7 mmol/1
vs 2.2 ± 0.4 mmol/1, respectively, N.S.).
Comparison of two calibrations of the sensor
The inverse of the in vivo sensitivity coefficientj
(1/x) is the parameter which describes the varia¬
tion in the subcutaneous glucose concentration
responsible for a one nA variation in the sensor
output, and can therefore be used in the algo¬
rithms of the insulin infusion control system. This
value was identical when calculated on the basis of
the plateaus reached before and after the insulin
injection (1.17 ± 0.19 mmol.l~l/nA), or of those
observed before-and after the glucose infusions
(1.21 it 0.18 mmol/1/nA, n — 13, NS). The corre¬
lation between these two values was r = 0.998 (y —
0.97x + 0.087 mmol/1/nA). Similarly the two es¬
timations of I() were identical (5.69 it 1.46.nA vs.
5.53 ± 1.53 nA, n = 13, NS) and well correlated (r
= 0.977, y = 1.04x — 0.38).
DISCUSSION
This work was undertaken to define a method of
calibration of a glucose sensor implanted in the
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Fig. 4 - Correlation between the estimation of subcutaneous
glucose concentration and the concomitant plasma glucose
level reached at low, basal and high glucose level plateaus
obtained during the experiments of insulin induced hypo-
glycaemia and glucose infusion. Each symbol represents a
different sensor (21 points for 7 sensors, r = 0.9987 ± 0.0002,
n = 7, Mean ± SEM).
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Fig. 3 - Plasma glucose concentration (circles) and apparent
subcutaneous glucose level (squares) during intravenous
glucose infusion: A) 20mg/kg/min, open symbols, n = 6; B)
20-60 mg/kg/min, closed symbols, n = 7. Glucose infusion
was initiated when a stable hypoglycaemic level was
achieved following the insulin injection (Fig. 2). Mean ±
SEM.
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Fig. 5 - Plasma glucose concentration (closed circles) and
apparent subcutaneous glucose level (closed squares) fol¬
lowing i.v. glucose injection (0.5 g/kg), administered when a
stable hypoglycaemic level was achieved following the insu¬
lin injection (Fig. 2). Mean ± SEM of 7 experiments.
subcutaneous tissue. This issue is critical since
this calibration will allow us to calculate, from the
sensor output, an estimation of the prevailing sub¬
cutaneous glucose concentration. This estimation,
processed by means of algorithms, will determine
the How rate of the pump delivering insulin, in a
closed-loop insulin delivery system. However, the
calibration of a subcutaneous implanted sensor
presents a specific difficulty, which is due to (he
fact that the relationship between the true subcu¬
taneous glucose concentration and the BG level is
unknown. For these reasons, Matthews et al. (5)
and Pfeiffer et al. (6) preferred to present the
sensor output expressed in nA, and not to propose
any transformation into an apparent glucose con¬
centration.
Shichiri et al. (3), and (llaremont et al. (4) cali¬
brated the glucose sensor on the basis of an in vitro
calibration, performed respectively in physiologi¬
cal saline, or in a buffered glucose solution. This
assumes, however, that both the current observed
in the absence ofglucose (l()) and the sensitivity of
the sensor are identical under both in vitro and in
vivo conditions. This might not be true, and might
be one explanation for the very low values of the
estimated glucose concentration in pig subcutane¬
ous tissue, which was only 20% of the concomitant
BG level (4). If we consider our experiments in rats,
the in vitro and in vivo values of I() obtained in each
experiment were correlated (r — 0.479, p < 0.05),
but we did not observe any correlation between the
values of the sensitivity coefficient, determined
under both conditions, (r = 0.146, n = 25), which
were found to be significantly different (p <C0.05),
with an unexpected higher value observed in vivo;
although we do not have an explanation for this
phenomenon, the absence of correlation between
in vitro and in vivo data suggests that it might be
hazardous to speculate on a difference observed
between data obtained under two completely dif¬
ferent situations. In addition, when some sensors
were tested in vitro in two different buffers (data
not shown), the observed sensitivity coefficients
were well correlated (r =0.98) but no correlation
was found between the observed values of I() (r =
0.668, n = 5). Claremont et al. tested their sensor
in vitro in a buffered glucose solution or in plasma;
they found similar values for I(), but a significantly
lower value for the sensitivity coefficient when the
sensor was tested in plasma (7). This suggests that
the in vitro characteristics of a glucose sensor
might depend on the choice of the buffer, which is
in any way different from the interstitial fluid
present in the subcutaneous tissue.
Abel et al. calibrated a glucose sensor implanted in
dogs, by adjusting the initial sensor output to the
BG concentration, and this in vivo calibration
procedure was used to determine the subcutane¬
ous glucose concentration during a subsequent
glucose infusion (8). However, this is a one-point
calibration procedure, and it assumes that the in
vivo value of I() was identical to the in vitro value. If
we consider the data obtained with our sensors,
both values, asjnentioned above were fairlv corre-
w
lated. It seems that this might have been the case
with their sensors, since in their experiments in
dogs, the estimated value of subcutaneous glucose
concentration remained verv close to BG level
w
during a glucose infusion, in accordance to our
data in rats.
To avoid these problems, we used an original in
vivo two-point calibration procedure, which made
it possible to transform, in each individual experi¬
ment, the recorded current into an estimation of
the subcutaneous glucose concentration, without
having to take into account the in vitro data. This
method allowed us to determine all the in vivo
characteristics of the sensor: sensitivity coeffi-
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cient, value of I(), and even, for some sensors, the
linearity range (Fig. 4). This figure is most impor¬
tant since it demonstrates that for each individual
sensor t he apparent subcutaneous glucose concen¬
trât ion, estimated with this method (and therefore
the sensor output from which it was calculated),
was linearly correlated to the corresponding BG
level, up to 13 mmol/1, although the sensor in vivo
calibration itself was performed at a much lower
level (between 6 and 3 mmol/1, Fig. 1). This vali¬
dates a posteriori the calibration procedure which
assumes that this relationship is linear. Further¬
more, this calibration can be carried out under
both upward and downward changes in BG concen¬
trations, provided that two steady levels of BG are
achieved. This might have practical implications
for the clinical use of a subcutaneous glucose sen¬
sor, since obviously it would be safer to use aj
calibration procedure based on an increase in BG
concentration: for instance, a two-point calibra¬
tion procedure could be achieved by using the data
of two successive BG determinations, performed
bv the patient before and after breakfast. Inciden¬
tally, the fact that these two estimations of the in
vivo sensitivity coefficient were identical, as were
the two estimations of this coefficient performed
in vitro, before and after the in vivo experiment,
suggest that the characteristics of the sensor did
not change over the duration of the experiment (4
hr). Finally, note that the upper limit of the in vitro
linearity range of the sensors was 18 mmol/1 glu¬
cose, and that the in vivo linearity range of the
sensors might actually exceed 13 mmol/1 (which
was the plateau value used in these experiments).
\\ e used this method of calibration to determine
the in vivo kinetics of the apparent subcutaneous
glucose concentration during glycaemic varia¬
tions. These kinetics are of paramount importance
for the design of the algorithms of a closed-loop
insulin delivery svstem. Our data in rats demon-j ~
strate that, 1. during insulin induced hvpoglycae-
mia and glucose inf usion, the apparent subcutane¬
ous glucose concentration follows BG with a 5 min
delay, which represented the integration of the
sensor response time and of glucose transfer time
from blood to subcutaneous fluid compartment.
Abel cl al. observed a slightly longer delay in dogs
(8), which might be due to the slower response
•time of t heir sensor, or to some difference bet ween
rat and dog subcutaneous tissues: 2. I nder steadyO -
state conditions, the apparent subcutaneous glu¬
cose concentration is linearly related to that ofBG
(Fig. 4), up to 13 mmol/1: 3. This might not be true
during an acute and transient change in BG con¬
centration, achieved during an i.v. glucose injec¬
tion. Although the peak BG concentration (12.4
mmol/1) remained in the in vivo linearity range of
the sensor, the peak in the apparent subcutaneous
glucose concentration was much less pronounced.
Claremont also observed a difference between
blood and subcutaneous glucose concentration
peaks following a glucose bolus (4). This différ¬
ence was probably due to the response time of the
sensor, to the glucose transfer time from blood to
subcutaneous tissue, and to the dilution of glucose
in the extracellular space, where it was monitored
by the sensor, the glycaemic peak being higher
than the subcutaneous peak because it was mea¬
sured before the intravascular and the extravascu-
lar glucose concentrations had reached an equili¬
brium.
11 has to be pointed out that we did not measure the
true subcutaneous glucose concentration, but a
function of the sensor current, which was referred
to throughout this text as an 'apparent" subcu¬
taneous glucose concentration. Nevertheless, two
different approaches of sampling interstitial fluid
in dogs, found that, under stationary conditions,
the true subcutaneous glucose concentration is
indeed identical to BG level: Fischer et al., by a
wick technique, using subcutaneously implanted
cotton threads (c)), and Janle-Swain et al. using a
subcutaneously implanted capillary f iltrate collec¬
tor (10). These data contrast with those obtained
bv Claremont in pigs (4) and Shichiri in dogs (3)
and in human diabetic patients (11), who found
lower values in the subcutaneous tissue. These
underestirnations may have been due to t he use, in
y
t hese later st udies, of m vitro determined sensitivi¬
ty coefficients to calculate the subcutaneous glu¬
cose concentration.
I n conclusion, we described an in vivo, rather than
an in vitro method for calibrating a subcutaneous
glucose sensor; this method made it possible to
characterize the relationship between BG and ap¬
parent subcutaneous levels, which were found to
be virt uallv identical during progressive glycaemic
changes, with a 5 min time lapse. Moreover, the
fact that these relationships were highly reprodu¬
cible (Figs. 2 and 3) demonstrates that this pa-
232 DNM, Vol. 1. N. 3
Subcutaneous glucose sensor
rameter is suitable to be processed in a closed-loop
insulin delivery system using appropriate algo¬
rithms. Thus, il these data, obtained in rats, are
relevant to man, I hey would validate subcutaneous
t J
tissue as a site for the implantation of a glucose
sensor, as part of an artificial endocrine pancreas.
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